• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罗马尼亚东北部转移性结直肠癌患者 KRAS、NRAS、BRAF、PIK3CA 和 TP53 基因突变的临床、病理和分子分析

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.

机构信息

Department of Medical Oncology, Regional Institute of Oncology, 700483 Iasi, Romania.

Department of Oncology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

出版信息

Int J Mol Sci. 2023 Aug 11;24(16):12679. doi: 10.3390/ijms241612679.

DOI:10.3390/ijms241612679
PMID:37628868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10454287/
Abstract

Mutations in RAS, BRAF, PIK3CA, and TP53 are well-established genetic abnormalities in metastatic colorectal cancer (mCRC). However, limited information is available for patients from Eastern Europe, including Romania. In this retrospective analysis, we investigated 104 mCRC patients from the Northeastern region of Romania to determine the frequency, distribution, coexistence, and clinicopathological and molecular correlations of these mutations. TP53 was the most frequently mutated gene (73.1%), followed by KRAS (45.2%) and PIK3CA (6.7%). Patients with KRAS mutant tumors and wild-type TP53 genotype were found to have no personal history of gastrointestinal cancer ( = 0.02, = 0.007). KRAS mutations in exon 3 were associated with the female gender ( = 0.02) and the absence of lymph node invasion ( = 0.02). PIK3CA mutations were linked to the absence of lymph node invasion ( = 0.006). TP53 mutations were associated with KRAS mutations in exon 2 ( = 0.006), ulcerated histopathologic type ( = 0.04), and G2 differentiation ( = 0.01). It provides novel insights into genetic variations specific to the population from Northeastern Romania, which has been underrepresented in previous studies within Eastern Europe. Furthermore, our findings enable the development of genetic profiles in a developing country with limited access to specialized genetic tests and facilitate comparisons with other populations.

摘要

RAS、BRAF、PIK3CA 和 TP53 基因突变是转移性结直肠癌(mCRC)中确立的遗传异常。然而,东欧包括罗马尼亚在内的患者的相关信息有限。在这项回顾性分析中,我们研究了来自罗马尼亚东北部的 104 名 mCRC 患者,以确定这些突变的频率、分布、共存以及与临床病理和分子的相关性。TP53 是突变频率最高的基因(73.1%),其次是 KRAS(45.2%)和 PIK3CA(6.7%)。KRAS 突变型肿瘤且 TP53 野生型基因型的患者没有胃肠道癌症的个人史( = 0.02, = 0.007)。KRAS 外显子 3 突变与女性性别( = 0.02)和无淋巴结侵犯有关( = 0.02)。PIK3CA 突变与无淋巴结侵犯有关( = 0.006)。TP53 突变与 KRAS 外显子 2 突变( = 0.006)、溃疡性组织病理学类型( = 0.04)和 G2 分化( = 0.01)有关。这为来自罗马尼亚东北部的人群的特定遗传变异提供了新的见解,而这些人群在之前的东欧研究中代表性不足。此外,我们的发现为一个专门遗传检测机会有限的发展中国家制定遗传图谱提供了可能,并促进了与其他人群的比较。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4511/10454287/0292e51d527e/ijms-24-12679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4511/10454287/0292e51d527e/ijms-24-12679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4511/10454287/0292e51d527e/ijms-24-12679-g001.jpg

相似文献

1
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.罗马尼亚东北部转移性结直肠癌患者 KRAS、NRAS、BRAF、PIK3CA 和 TP53 基因突变的临床、病理和分子分析
Int J Mol Sci. 2023 Aug 11;24(16):12679. doi: 10.3390/ijms241612679.
2
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.在一个大型局部晚期直肠癌患者前瞻性系列中分析 KRAS、NRAS、BRAF、PIK3CA 和 TP53 突变。
Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5.
3
KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.罗马尼亚东南部结直肠癌患者的 KRAS、NRAS、BRAF、PIK3CA 和 AKT1 特征。
Medicine (Baltimore). 2022 Oct 7;101(40):e30979. doi: 10.1097/MD.0000000000030979.
4
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.印度结直肠癌患者中KRAS、BRAF、PIK3CA、NRAS、TP53和APC基因突变的患病率及共存情况:基于二代测序的队列研究
Tumour Biol. 2017 Feb;39(2):1010428317692265. doi: 10.1177/1010428317692265.
5
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.表皮生长因子受体途径的效应器:结直肠癌特征及个性化医疗中KRAS、BRAF、PIK3CA、NRAS突变的基因图谱分析
PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.
6
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.原发性和转移性结直肠癌中神经内分泌分化与KRAS/NRAS/BRAF/PIK3CA/TP53突变状态的比较
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.
7
PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes.PIK3CA 突变而 KRAS、NRAS 和 BRAF 无突变的结直肠癌存在表观遗传修饰和 DNA 损伤反应基因的常见潜在可靶向突变。
Cancer Genomics Proteomics. 2024 Sep-Oct;21(5):533-548. doi: 10.21873/cgp.20470.
8
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.KRAS、BRAF、NRAS 和 PIK3CA 基因突变对西妥昔单抗联合化疗治疗化疗耐药转移性结直肠癌疗效的影响:一项回顾性联盟分析。
Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.
9
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.353 例中国结直肠癌患者 KRAS、NRAS、BRAF 和 PIK3CA 的突变状态及预后价值。
Sci Rep. 2018 Apr 17;8(1):6076. doi: 10.1038/s41598-018-24306-1.
10
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.KRAS、NRAS、BRAF 和 PIK3CA 基因突变率、临床病理相关性及其在伊朗结直肠癌患者中的预后价值。
J Clin Lab Anal. 2023 Mar;37(5):e24868. doi: 10.1002/jcla.24868. Epub 2023 Mar 17.

引用本文的文献

1
Comparison of somatic mutations and clinicopathologic features of micropapillary and non-micropapillary colorectal carcinomas.微乳头型与非微乳头型结直肠癌的体细胞突变及临床病理特征比较
BMC Cancer. 2025 Jul 1;25(1):1100. doi: 10.1186/s12885-025-14487-0.
2
Precision medicine in colorectal cancer: genomics profiling and targeted treatment.结直肠癌的精准医学:基因组分析与靶向治疗。
Front Pharmacol. 2025 Feb 27;16:1532971. doi: 10.3389/fphar.2025.1532971. eCollection 2025.
3
KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients.

本文引用的文献

1
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.KRAS 突变至关重要:转移性结直肠癌中 KRAS 突变的预后及预测价值的观察性研究
Front Oncol. 2022 Nov 29;12:1055019. doi: 10.3389/fonc.2022.1055019. eCollection 2022.
2
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.转移性结直肠癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.
3
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
KRAS突变状态与罗马尼亚结直肠癌患者临床病理特征的关系
Curr Issues Mol Biol. 2025 Feb 12;47(2):120. doi: 10.3390/cimb47020120.
4
mA Reader PRRC2A Promotes Colorectal Cancer Progression via CK1ε-Mediated Activation of WNT and YAP Signaling Pathways.mA阅读器PRRC2A通过CK1ε介导的WNT和YAP信号通路激活促进结直肠癌进展。
Adv Sci (Weinh). 2025 Jan;12(3):e2406935. doi: 10.1002/advs.202406935. Epub 2024 Nov 24.
5
Stage-based colorectal cancer prediction on uncertain dataset using rough computing and LSTM models.基于粗糙集和 LSTM 模型的不确定数据集阶段式结直肠癌预测。
Sci Rep. 2024 Nov 21;14(1):28880. doi: 10.1038/s41598-024-77302-z.
6
Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.结直肠癌患者 KRAS 和 TP53 基因突变的联合增强了化学耐药性,从而促进术后复发和转移。
BMC Cancer. 2024 Sep 17;24(1):1155. doi: 10.1186/s12885-024-12776-8.
7
Comparative Expression Analysis of Tumor Suppressor and Oncogene in Colorectal Adenocarcinoma.结直肠癌中肿瘤抑制基因与癌基因的比较表达分析
Cancer Diagn Progn. 2024 Mar 3;4(2):129-134. doi: 10.21873/cdp.10298. eCollection 2024 Mar-Apr.
8
Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis.探讨结直肠癌转移的潜在表观遗传生物标志物。
Int J Mol Sci. 2024 Jan 10;25(2):874. doi: 10.3390/ijms25020874.
9
Long-term trends in the burden of colorectal cancer in Europe over three decades: a joinpoint regression and age-period-cohort analysis.欧洲三十年来结直肠癌负担的长期趋势:连接点回归和年龄-时期-队列分析
Front Oncol. 2023 Dec 5;13:1287653. doi: 10.3389/fonc.2023.1287653. eCollection 2023.
10
Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer.保加利亚晚期转移性结直肠癌患者的突变状态。
Int J Mol Sci. 2023 Aug 13;24(16):12753. doi: 10.3390/ijms241612753.
瑞士 512 例结直肠癌患者通过常规诊断中的靶向下一代测序分析的分子改变的流行率。
Pathobiology. 2023;90(3):166-175. doi: 10.1159/000526117. Epub 2022 Oct 6.
4
Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.结直肠癌中 p53 蛋白表达和 TP53 变异状态的临床意义。
BMC Cancer. 2022 Aug 31;22(1):940. doi: 10.1186/s12885-022-10039-y.
5
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies.结直肠癌:致癌作用、全球流行病学、当前挑战、风险因素、预防与治疗策略综述
Cancers (Basel). 2022 Mar 29;14(7):1732. doi: 10.3390/cancers14071732.
6
-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.- 转移性结直肠癌的一个真实病例及三个基于人群的北欧队列中的G12C突变
Front Oncol. 2022 Feb 16;12:826073. doi: 10.3389/fonc.2022.826073. eCollection 2022.
7
Global colorectal cancer burden in 2020 and projections to 2040.2020年全球结直肠癌负担及到2040年的预测。
Transl Oncol. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174. Epub 2021 Jul 6.
8
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.丹麦结直肠癌患者 KRAS、NRAS、BRAF 和 PIK3CA 基因突变的频率和共存以及 MMR 缺陷的发生情况。
APMIS. 2021 Feb;129(2):61-69. doi: 10.1111/apm.13091. Epub 2020 Nov 6.
9
BRAF Mutated Colorectal Cancer: New Treatment Approaches.BRAF 突变型结直肠癌:新的治疗方法
Cancers (Basel). 2020 Jun 14;12(6):1571. doi: 10.3390/cancers12061571.
10
The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.转移性结直肠癌中 RAS 和 BRAF 突变的共存:病例报告和系统文献复习。
J Gastrointestin Liver Dis. 2020 Jun 3;29(2):251-256. doi: 10.15403/jgld-1003.